Reductions to market exclusivity and other incentives could “drive investment away”, pharma body claims
Changes being considered to EU rules around medicines for children and rare diseases could hamper R&D in these areas, Europe’s umbrella body for the pharmaceuticals industry has warned.
The European Federation of Pharmaceutical Industries and Associations issued the warning in its response to a consultation being carried out by the European Commission, which will propose updates to the rules in 2022.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.